Symptoms of RSV infections can be reversed. Patients with severe wheezing as a result of recurrent respiratory syncytial virus infections can be treated with aerosolized budesonide, and there is a higher response to treatments with corticosteroid inhalants. However, these treatments are typically reserved for children who are otherwise healthy, and they may be expensive. The use of systemic steroids for the treatment of RSV infections in non-influenza patients should be discouraged if other options are available.
RSV is the most common respiratory virus responsible for hospitalizations in children younger than 13 years old. About 12.5% of U.S. children are estimated to have a RSV infection in a given year.
RSV has a worldwide incidence, but is associated with lower respiratory diseases. These infections have an important economic burden worldwide. The immunological processes of RSV infection are well recognised, especially its initiation, during which a cascade of cytokines and chemokines take part in the inflammatory response.
RSV infections cause the majority of lower respiratory tract syndromes. They usually resolve after 3–5 days of oral antiviral therapy. Treatment with inhaled corticosteroid therapy is most often indicated.
Common treatments for RSV (most commonly RSV pneumonia and bronchiolitis in young children and acute lower respiratory tract infection (LLRTI) in older children and adults) include steroids, anti-RSV antibodies, antiviral drugs, and antiviral prophylaxis. Appropriate dosing depends on the severity of the disease (e.g. length of illness, number of viral episodes, severity of symptoms, immune status of the patient). Steroids are sometimes prescribed prior to RSV infection to reduce the impact of upper respiratory infection. However, they appear to increase the severity of RSV in affected infants and children. Consequently, their use is generally not recommended.
The most common clinical signs include: a runny nose, bronchiolitis, fever, and hoarseness. Other clinical signs of RSV infections are wheezing, croup and a cough. Signs of the influenza virus are often confused with those of RSV infections especially if an acute RSV infection develops after the influenza infection.
The Lumiradx Sars-cov-2 (ThermoFisher Scientific) is a lumiradx-based in vitro detection kit that aims to detect Sars-cov-2 in both blood, nasal secretions and cerebrospinal fluid. This kit is an in vitro kit for the detection of Sars-Cov-2 in blood, nasal secretions and cerebrospinal fluid of patients with a suspicion of Sars-CoV infection. The flu A/B test kit by the same manufacturer is based on a Lumiradx Sars-cov-2 detection system plus a Lumiradx nucleic acid amplification test for detection of viral RNA.
Lumiradx sars-cov-2 & flu a/b test improves quality of life in adults with RSMV irrespective of comorbid diagnoses, including for those who may be under-diagnosed with RSMV in the absence of symptoms.
Lumiradx did not appear to be clinically useful in predicting the need for hospitalisation at one year. This may be explained by the relatively small sample size in this study and the short duration of the study. Further longer-term studies are needed.
There is a wide age range of respiratory syncytial virus infections. The average age that someone gets sick during an infection is 1-2 years, and 10-15% of the time, it will be in their first year. It is important to know that a lot of this infection happens in people over the age of 65 years.
There are a number of clinical trials currently utilizing immunoglobulin in patients with sars-cov-2. To date, no clinical trials testing for sars-cov-2 antibodies in patients with respiratory syncytial virus infection have been reported in the literature, though the current evidence supports this hypothesis.
[No] people treated with lumiradx sars-cov-2 are at higher risk of progressing to severe disease. The sars-cov-2 test should only be done if the patient presents symptoms of ARDS or severe pneumonia and if treatment is going to be administered.